Author

Bertrand Paguet

Observed names: B. Paguet, Paguet Bertrand, Paguet, Bertrand

Institution: Novartis (Switzerland)

Observed institution: Novartis (Switzerland)

OpenAlex ID: A5033661111

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

2020 · J. Bagel, A. Blauvelt, et al. · Journal of the European Academy of Dermatology and Venereology · 50

Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial

2024 · Alexa B Kimball, Falk G Bechara, et al. · British Journal of Dermatology · 19

Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial

2021 · Bardur Sigurgeirsson, John Browning, et al. · Dermatologic Therapy · 16

27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE

2021 · Bardur Sigurgeirsson, John Browning, et al. · Journal of the American Academy of Dermatology · 5

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

2025 · Andrzej Kaszuba, Philemon Papanastasiou, et al. · Journal of the European Academy of Dermatology and Venereology · 3

75099 Four-year efficacy of continuous secukinumab in SUNSHINE/SUNRISE core and extension trials on hidradenitis suppurativa (HS) lesions

2026 · Vivian Shi, Jennifer Hsiao, et al. · Journal of the American Academy of Dermatology

64857 The impact of continuous secukinumab treatment through week 104 on efficacy outcomes in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials

2025 · Alexa Kimball, Dimitrios Ioannides, et al. · Journal of the American Academy of Dermatology

64674 The impact of continuous secukinumab treatment through week 104 on patient reported outcomes in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials

2025 · Alexa Kimball, Dimitrios Ioannides, et al. · Journal of the American Academy of Dermatology

52620 Long-term safety and efficacy of secukinumab over 236 weeks in children and adolescents with severe chronic plaque psoriasis: Results of a double-blind, randomized controlled phase III trial

2024 · Shoba Ravichandran, Andrzej Kaszuba, et al. · Journal of the American Academy of Dermatology

L’administration du sécukinumab par un auto-injecteur de 2 mL démontre une efficacité élevée avec une sécurité et une tolérance comparables chez les patients adultes atteints de psoriasis en plaques : résultats à 16 semaines de l’étude MATURE

2021 · Bardur Sigurgeirsson, John Browning, et al. · Annales de Dermatologie et de Vénéréologie - FMC

Chez les patients adultes atteints de psoriasis en plaques pesant 90 kg ou plus, le sécukinumab administré toutes les 2 semaines démontre une efficacité supérieure, et bénéficie aux patients non-répondeurs PASI 90 à la semaine 16

2021 · Kristian Reich, Matthias Augustin, et al. · Annales de Dermatologie et de Vénéréologie - FMC

Biochemical characterization and three-dimensional structure analysis of the yeast cleavage and polyadenylation factor CPF

2008 · Paguet, Bertrand · edoc (University of Basel)

Works count: 13

Citation count: 93

H-index: 4

I10-index: 3